首页> 中文期刊> 《亚洲药物制剂科学(英文)》 >Oxidation-strengthened disulfide-bridged prodrug nanoplatforms with cascade facilitated drug release for synergetic photochemotherapy

Oxidation-strengthened disulfide-bridged prodrug nanoplatforms with cascade facilitated drug release for synergetic photochemotherapy

         

摘要

One of the major barriers in utilizing prodrug nanocarriers for cancer therapy is the slow release of parent drug in tumors.Tumor cells generally display the higher oxidative level than normal cells,and also displayed the heterogeneity in terms of redox homeostasis level.We previously found that the disulfide bond-linkage demonstrates surprising oxidationsensitivity to form the hydrophilic sulfoxide and sulphone groups.Herein,we develop oxidation-strengthened prodrug nanosystem loaded with pyropheophorbide a(PPa)to achieve light-activatable cascade drug release and enhance therapeutic efficacy.The disulfide bond-driven prodrug nanosystems not only respond to the redox-heterogeneity in tumor,but also respond to the exogenous oxidant(singlet oxygen)elicited by photosensitizers.Once the prodrug nanoparticles(NPs)are activated under irradiation,they would undergo an oxidative self-strengthened process,resulting in a facilitated drug cascade release.The IC50 value of the PPa@PTX-S-S NPs without irradiation was 2-fold higher than those of NPs plus irradiation.In vivo,the PPa@PTX prodrug NPs display prolonged systemic circulation and increased accumulation in tumor site.The PPa@PTXS-S NPs showed much higher efficiency than free PTX or the PPa@PTX-C-C NPs to suppress the growth of 4 T1 tumors.Therefore,this novel oxidation-strengthened disulfide-bridged prodrug-nanosystem has a great potential in the enhanced efficacy of cancer synergetic photochemotherapy.

著录项

  • 来源
    《亚洲药物制剂科学(英文)》 |2020年第5期|P.637-645|共9页
  • 作者单位

    Wuya College of Innovation Shenyang Pharmaceutical University Shenyang 110016 ChinaDepartment of Laboratory Medicine The First Affiliated Hospital China Medical University Shenyang 110001 China;

    Ministry of Education Heilongjiang University Harbin 150500 ChinaSino-Russian Joint Graduate School Heilongjiang University Harbin 150080 China;

    Wuya College of Innovation Shenyang Pharmaceutical University Shenyang 110016 China;

    Wuya College of Innovation Shenyang Pharmaceutical University Shenyang 110016 China;

    Department of Laboratory Medicine The First Affiliated Hospital China Medical University Shenyang 110001 China;

    Wuya College of Innovation Shenyang Pharmaceutical University Shenyang 110016 China;

    Wuya College of Innovation Shenyang Pharmaceutical University Shenyang 110016 China;

    Wuya College of Innovation Shenyang Pharmaceutical University Shenyang 110016 China;

    Wuya College of Innovation Shenyang Pharmaceutical University Shenyang 110016 China;

    Wuya College of Innovation Shenyang Pharmaceutical University Shenyang 110016 China;

    Wuya College of Innovation Shenyang Pharmaceutical University Shenyang 110016 China;

    Department of Laboratory Medicine The First Affiliated Hospital China Medical University Shenyang 110001 China;

    School of Life Science and Biopharmaceutics Shenyang Pharmaceutical University Shenyang 110016 China;

    School of Life Science and Biopharmaceutics Shenyang Pharmaceutical University Shenyang 110016 China;

    Ministry of Education Heilongjiang University Harbin 150500 ChinaSchool of Life Sciences Heilongjiang University Harbin 150080 China;

    Wuya College of Innovation Shenyang Pharmaceutical University Shenyang 110016 China;

  • 原文格式 PDF
  • 正文语种 chi
  • 中图分类 肿瘤学;
  • 关键词

    Prodrug nanoplatform; Disulfide bond; Pyropheophorbide a; Redox-heterogeneity; Accurate therapy;

    机译:前药纳米片;二硫键;纤维素键A;氧化还原异质性;准确的治疗;
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号